Jagsonpal Pharmaceuticals Ltd

Know More
NSEBSE

308.051.20 (0.39%)

12:49 PM,5th Mar 2024

308.901.50 (0.49%)

01:02 PM,5th Mar 2024

BSE : 507789

NSE : JAGSNPHARM

Sector : Health care

ISIN Code : INE048B01027

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Mar 05 2024 | 01:02 PM IST

Market Cap (₹ Cr)

811

Turnover (₹ Cr)

0.03

Volume (Shares)

10046

Face Value

5

52-WK High

514.85

52-WK High Date

31 Jul 2023

52-WK Low

285.00

52-WK Low Date

27 Mar 2023

All Time High

514.85

All Time High Date

31 Jul 2023

All Time Low

6.00

All Time Low Date

27 Oct 2008

Jagsonpal Pharmaceuticals Ltd

Promoted by J S Kochhar in 1978 Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary Jagsonpal Exports India Pvt Ltd.The company has a strategic alliance with Fidia Spa Italy; and B Spofola Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company Makhteshim Chemical Works for acquiring the marketing rights of an anti-oxidant product. In 1994 the company has also promoted Aresco Financial Services a new financial company.The Company's R&D activities have resulted in manufacturing process upgradation improving packaging and cost containment. It's R&D activities are geared towards development of new product technologies which can be commercialised in future.It has tied up with Lycored Natural Products Industries (LNP) of Israel to launch a completely natural Lycopene bioactive product Lycored in India and SouthEast Asia.In the fiscal 2001 the company's sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds such as sluggish market trends lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

Jagsonpal Pharmaceuticals Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

811

EPS - TTM (₹) [S]

9.31

P/E Ratio (X) [S]

4.79

Face Value (₹) 5
Latest Dividend (%)100.00
Latest Dividend Date 21 Aug 2023
Dividend Yield (%) 1.63
Book Value Share (₹) [S]64.35
P/B Ratio (₹) [S]4.79
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
Motilal Oswal S&P BSE Healthcare ETF 0.00 83 0.03

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

301.25

310.00

Week Low/High

294.00

313.00

Month Low/High

288.00

362.00

Year Low/High

285.00

515.00

All time Low/High

1.38

515.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week0.03%0.37%0.970.65%
1 Month1.03%1.00%2.892.62%
3 Month-25.55%-25.70%6.517.13%
6 Month-27.45%-27.46%12.2014.14%
1 Year-1.52%-2.10%23.4126.99%
3 Year239.64%240.39%46.4349.57%

Company Info

Company Information

Managing Director : Manish Gupta

Chairman & Non Executive Dir. : Harsha Raghavan

Independent Director : Debasis Bikash Nandy

Independent Director : Radhika Dudhat

Independent Director : Pallavi Dinodia

Non Executive Director : Prithipal Singh Kochhar

Company Sec. & Compli. Officer : Abhishek Joshi

Registered Office: T-210 J, Shahpur Jat,New Delhi,New Delhi-110049 Ph: 91-011-46181100/46109900

Email:nandita.singh@jagsonpal.com

URL:http://www.jagsonpal.com